Skip to main content

Individual Drug Analyses

This page contains a complete list of all FDA analyses conducted in the Sentinel System from the start of Mini-Sentinel in 2009 to the present. 

The table below is organized at the individual analysis level (e.g., Level 1, Level 2, Query Builder, protocol-based assessment, etc.). It is designed to support searches for a specific analysis. 

Alternatively, the Drug Studies table groups together related analyses that FDA conducted to address a safety concern, or set of related safety concerns. The Drug Studies page also provides important background information and describes the regulatory impact.

Note: The appearance of a drug in a Sentinel study does not mean that FDA has concluded that a causal relationship exists between the drug and the health outcome of interest. Patients and healthcare providers should refer to FDA.gov for further information about drug safety.

FDA Sentinel Analyses from ARIA and Other Sentinel Data Sources

Title Medical Product Outcomes Date
Incidence of Inflammatory Bowel Disease Following Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Use in Patients with Type 2 Diabetes Mellitus: An Inverse Probability of Treatment Weighting Analysis
Retrospective Inferential
dipeptidyl peptidase-4 (DPP-4) inhibitors
inflammatory bowel disease (IBD)
Utilization Patterns of Diabetes Mellitus and Anti-Obesity Drugs: A Descriptive Analysis
Descriptive
Mometasone Furoate Sinus Implant Use in Patients with Nasal Polyps: An Updated Descriptive Analysis
Descriptive
mometasone sinus implant
Characterization of Mothers in the Mother-Infant Linkage Table in the Sentinel Distributed Database: An Updated Descriptive Analysis
Descriptive
Prevalent and Incident Use of Bortezomib: A Descriptive Analysis
Summary Table
Siponimod Use During Pregnancy: A Descriptive Analysis
Descriptive
use in pregnancy
Siponimod Use Among Female Patients: A Descriptive Analysis
Descriptive
Trends in Single-Dose Doxycycline for Lyme Disease Prophylaxis in the United States: A Third Descriptive Analysis
Descriptive
Risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Following Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Use in Patients with Type 2 Diabetes Mellitus
Retrospective Inferential
glucagon-like peptide-1 receptor agonists (GLP-1 RAs)
non-arteritic anterior ischemic optic neuropathy
Characterization of Confounding Covariates in the TriNetX: A Descriptive Analysis
Descriptive